Findings on weight‐loss drugs offer hope, but caution needed

Addiction researchers continue to preach caution amid a flurry of findings suggesting that popular weight‐loss medications such as semaglutide could have important applications in treating substance use disorders (SUDs). The latest report found a decreased risk of alcohol use disorder‐related hospitalization in patients who use semaglutide or liraglutide and its lead investigator is echoing the call for evidence from randomized trials to confirm conclusions drawn from observational studies.